U.S. License Holder:
Date of License:
WEZLANA (ustekinumab-auub) is a human interleukin -12 and -23 antagonist indicated for the treatment of:
Adult patients with:
Moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy;
Active psoriatic arthritis (PsA);
Moderately to severely active Crohn's disease (CD);
Moderately to severely active ulcerative colitis.
Pediatric patients 6 years and older with:
Moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy;
Active psoriatic arthritis (PsA).
U.S. Patent LitigationsPACER
U.S. Patent Nos.
6,902,734 (Anti-IL-12 Antibodies and Compositions Thereof) 8,852,889 (Cell Culture Process) 9,217,168 (Methods of Cell Culture) 9,475,858 (Cell Culture Process) 9,663,810 (Methods of Cell Culture) 10,961,307 (Methods of Treating Moderately to Severely Active Ulcerative Colitis by Administering an Anti-IL12/IL23 Antibody)
Janssen Biotech, Inc.
Stipulated Dismissal Due to Settlement